Loading page...
Loading page...
This round is closed. The next round and similar open calls are listed below. Synced from the EU Funding & Tenders Portal on 9 November 2026.
This call is closed. These open or upcoming calls fund the closest work.
Based on projects the EU funded on the same subject in this programme.
KEEPCARINGFuture Proofing Health- and Care Systems Safeguarding Health Care Workers in Hospital Settings
HORIZON-HLTH-2023-CARE-04-02 · 2024 · Official record ↗
CARE-IN-HEALTHCArdiovascularREsolution of INflammation to promote HEALTH
HORIZON-HLTH-2022-STAYHLTH-02-01 · 2023 · Official record ↗
SP-EUSocial Prescribing to promote and improve access to health and care services for people in vulnerable situations in Europe
HORIZON-HLTH-2024-CARE-04-04-two-stage · 2025 · Official record ↗
ENACTEnvironmental Effect on Health Care and Wellbeing and Active Interventions
HORIZON-HLTH-2024-ENVHLTH-02-06-two-stage · 2025 · Official record ↗
BE READY NOWBE READY NOW - EUROPEAN PARTNERSHIP FOR PANDEMIC PREPAREDNESS
HORIZON-HLTH-2024-DISEASE-12-01 · 2026 · Official record ↗
suHCOSystemic Sustainability Transition Solution for Health Care Organisations through PCP
HORIZON-HLTH-2024-CARE-14-01 · 2025 · Official record ↗
DYNAMOModelling and dynamic assessment of integrated health and care pathways enhancing response capacity of health systems
HORIZON-HLTH-2022-CARE-08-02 · 2023 · Official record ↗
BEST-COSTBurden of disease based methods for estimating the socio-economic cost of environmental stressors
HORIZON-HLTH-2022-ENVHLTH-04-01 · 2023 · Official record ↗
Each one links to its EU funding record and the partners it works with: a starting list for building a consortium.
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Living and working in a health-promoting environment”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to most of the following expected outcomes:
The health sector accounts for nearly 5% of global greenhouse gas (GHG) emissions and generates significant demands for energy and materials, as well as dangerous polluting streams. Proactive mitigation efforts in the health sector can significantly reduce GHG emissions and pollution, saving many lives and contributing to relieve pressures on biodiversity and ecosystem services. However, specific mechanisms for emission reductions in the health sector remain less defined compared to those in other sectors.
At the same time, the climate crisis subjects healthcare systems to unprecedented pressures (e.g. on infrastructure, workforce, overall systems) while simultaneously having to respond to increasing healthcare needs. To reduce pressure in healthcare systems and generally improve public health, it is crucial to design inclusive and accessible interventions that prevent the health impacts of climate change and related environmental degradation, increase resilience and preparedness of individuals and communities and foster the adoption of health-protective behaviours.
Research activities under this topic should generate evidence on the opportunities and health co-benefits of mitigation in the health sector as well as foster the development of low-carbon medical technologies and digital solutions for the sector. Proposals should also support the design of effective, scalable, cost-effective and transferable interventions and frameworks that can be applied across a wide range of healthcare settings and/or in population, community and societal contexts and involving, when relevant, public and patient engagement. Proposals can consider both living and working environments.
More specifically research actions under this topic should include some of the following activities:
Funded projects under this topic should consider the scalability and transferability of the developed solutions to ensure that any knowledge, frameworks, methodologies, pilots, etc., developed are actionable and applicable across different healthcare settings and community contexts. Proposals should also consider the use of implementation science approaches to support the relevance and broad applicability of the research outcomes. Proposals should take into consideration the broader socio-economic challenges faced by healthcare systems (e.g. funding challenges, workforce shortages, population ageing and increase of chronic diseases). Additionally, solutions and interventions proposed under this topic should consider the Do No Significant Harm principle.
In order to maximise synergies and increase the impact of the projects, all proposals selected for funding from this topic will form a cluster and be required to participate in common networking and joint activities. Guidance on the potential activities to be developed can be obtained by consulting the clusters of projects ongoing under the Environment, Climate and Health research portfolio[1].
International cooperation is encouraged.
Proposals should make sure that relevant activities, outcomes and outputs are shared with the European Climate and Health Observatory[2] through the cluster that will be formed after the approval of the proposals. When relevant proposals should build on the outcomes of the projects that are part of the European Climate-Health Cluster[3].
Proposals are encouraged to consider, where relevant, the data, expertise and services offered by European research infrastructures[4] in the environment and health domain.
This topic requires the effective contribution of social sciences and humanities (SSH) disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities.
Applicants envisaging to include clinical studies[5] should provide details of their clinical studies in the dedicated annex using the template provided in the submission system.
[1] https://research-and-innovation.ec.europa.eu/research-area/health/environment-climate-and-health_en
[2] https://climate-adapt.eea.europa.eu/en/observatory
[3] https://climate-health.eu
[4] The catalogue of European Strategy Forum on Research Infrastructures (ESFRI) research infrastructures portfolio can be browsed on the ESFRI website: https://ri-portfolio.esfri.eu
[5] Please note that the definition of clinical studies (see introduction to this Work Programme part) is broad and it is recommended that you review it thoroughly before submitting your application.
1. Admissibility Conditions, proposal page limit and layout
Admissibility conditions are described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.
Proposal page limits and layout are described in Part B of the Application Form available in the Submission System.
2. Eligible Countries
Eligible countries are described in Annex B of the Work Programme General Annexes.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
3. Other Eligibility Conditions
In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.
If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).
Other eligibility conditions are described in Annex B of the Work Programme General Annexes.
4. Financial and operational capacity and exclusion
Financial and operational capacity and exclusion are described in Annex C of the Work Programme General Annexes.
5a. Evaluation and award: Award criteria, scoring and thresholds
Award criteria, scoring and thresholds are described in Annex D of the Work Programme General Annexes.
5b. Evaluation and award: Submission and evaluation processes
The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold will be 12.
Submission and evaluation processes are described in Annex F of the Work Programme General Annexes and the Online Manual.
5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
Indicative timeline for evaluation and grant agreement are described in Annex F of the Work Programme General Annexes.
6. Legal and financial set-up of the grants
In order to maximise synergies and increase the impact of the projects, all proposals selected for funding from this topic will form a cluster and be required to participate in common networking and joint activities (and in determining modalities for their implementation and the specific responsibilities of projects). These activities will be included in a dedicated work package, having sufficient budget allocated to it (around 2% of the total requested budget). Depending on the scope of proposals selected for funding, these activities may include:
The granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5.
Eligible costs will take the form of a lump sum as defined in the Decision of 7 July 2021 authorising the use of lump sum contributions under the Horizon Europe Programme – the Framework Programme for Research and Innovation (2021-2027) – and in actions under the Research and Training Programme of the European Atomic Energy Community (2021-2025) [[This decision is available on the Funding and Tenders Portal, in the reference documents section for Horizon Europe, under ‘Simplified costs decisions’ or through this link: https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/ls-decision_he_en.pdf]].
Legal and financial set-up of the grants are described in Annex G of the Work Programme General Annexes.
Specific conditions are described in the specific topic of the Work Programme.
Application and evaluation forms and additional documents:
Application and evaluation form templates
Standard application form (HE RIA, IA) - the application form specific to this call is available in the Submission System
Standard evaluation form (HE RIA, IA) - will be used with the necessary adaptations
Guidance
HE Programme Guide
Model Grant Agreement (MGA)
Lump Sum MGA
Call-specific instructions 
Information on clinical studies (HE)
Detailed budget table (HE LS) 
Guidance: "Lump sums - what do I need to know?"
Additional documents
HE Main Work Programme 2026-2027 – 1. General Introduction
HE Main Work Programme 2026-2027 – 4. Health
HE Main Work Programme 2026-2027 – 15. General Annexes
HE Programme Guide
HE Framework Programme 2021/695
HE Specific Programme Decision 2021/764
EU Financial Regulation 2024/2509
Decision authorising the use of lump sum contributions under the Horizon Europe Programme
Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
EU Grants AGA — Annotated Model Grant Agreement
Funding & Tenders Portal Online Manual
Funding & Tenders Portal Terms and Conditions
Funding & Tenders Portal Privacy Statement
Applicants asked the EU 11 questions about this call and the EU published the answers. They clarify the call documents but do not replace them.
There are no mandatory requirements for the proposals in this regard. However, the objective of this call is not for proposals to be overly broad and encompass many activities. Instead, it is preferred that they build robust submissions that excellently address particular aspects within the scope.
In any case, proposals are required to include at least two of the activities outlined within the scope. As long as this minimum threshold of two activities is met, the proposal will be considered within scope and valid.
Read it on the EU portal ↗Answered 11 Mar 2026
International collaboration is encouraged under this topic. In this regard, collaboration with eligible non-EU countries and low- and middle-income countries (LMICs) is not only possible but also encouraged if it brings added value to the proposal.
Depending on the focus of the proposal, incorporating partners from diverse international backgrounds could enhance the proposal's impact and provide broader perspectives, potentially strengthening its overall contribution to the call's objectives.
Read it on the EU portal ↗Answered 11 Mar 2026
Yes, this is a Lump Sum topic, as stipulated in the specific conditions of the topic. To define and justify the Lump Sum, you need to provide a detailed budget table with cost estimations (downloadable as an Excel file form the online submission system). The estimations must be an approximation of your actual costs and meet the eligibility criteria of Horizon Europe.
In order to facilitate the evaluation of your proposal, you are encouraged to use the comments part of the detailed budget table and provide any details / explanations that are needed to better understand the specificities of your proposal. You are also advised to systematically justify any deviations in personnel costs.
Moreover, if your lump sum budget contains any cost items in cost category C and/or D, please make sure to justify these items in the comments part of the detailed budget table, as the proposal template has been simplified by removing this information from Part B and bringing it closer to the relevant budget items. Specifically, you must include justifications in the comments part of the detailed budget table if you are in any of the following situations:
Read it on the EU portal ↗Answered 6 Nov 2026
Please note that the definition of clinical studies, together with additional useful information can be found in the introduction of Health Cluster Work Programme part for 2026-2027.
Additionally, we would like to bring to your attention the fact that the World Health Organization (WHO) has published a “Guidance for best practices for clinical trials”. You are not required not follow this guidance, however we encourage you to do so.
Finally, we would also like to encourage you to consider the latest innovations and advances in the clinical trial design and research methods in order to evaluate promising interventions allowing shorter development timings.
Read it on the EU portal ↗Answered 28 Jun 2026
Proposals do not have to address both adaptation and mitigation simultaneously.
Some activities within the scope are focused on adaptation, while others are centred around mitigation. A proposal may choose to concentrate on two or more of the suggested activities within a single area, either adaptation or mitigation or also on a mix of both depending on the focus of the proposal.
Read it on the EU portal ↗Answered 11 Mar 2026
No, it simply means that proposals should cover a majority of the expected outcomes of this topic, i.e. three or more outcomes out of the five outcomes enumerated in the topic.
Scoring during evaluations or funding opportunities are not dependent on the total number of outcomes covered by a specific proposal, as long as most of them are covered as required in this topic.
Read it on the EU portal ↗Answered 11 Mar 2026
Indeed, topic 04 focuses on mitigating the healthcare sector's impact on climate change and/or on reducing the effects of climate change on healthcare systems, populations, and communities. In fact, some activities within the scope are adaptation-focused, while others are mitigation-focused.
A proposal can choose to concentrate on two or more of the suggested activities within either adaptation or mitigation and still be considered valid.
In summary, it is not necessary to address both aspects (adaptation and mitigation), as long as the proposal includes at least two of the activities outlined in the scope.
Read it on the EU portal ↗Answered 11 Mar 2026
The study of mitigation-related co-benefits can take place in sectors other than the health sector, provided that proposals can substantiate why mitigation in these other sectors could lead to significant health co-benefit impacts.
Read it on the EU portal ↗Answered 11 Mar 2026
"frameworks" in the context of this call means the development of guidelines, methodologies and approaches devised for assessing, measuring, and making decisions related to greening, decarbonising, or adapting to climate change.
Read it on the EU portal ↗Answered 11 Mar 2026
The requirement for evaluations will largely depend on the specific activities selected by each proposal.
Yes, some form of evaluation of potential interventions will be necessary to assess their effectiveness, accessibility, and impact. However, there is no specified minimum number of interventions or case studies required.
Read it on the EU portal ↗Answered 11 Mar 2026
The Health Cluster Work Programme part for 2026-2027 includes a “right to object” condition for nearly all topics, giving the granting authority the right to object to a transfer of ownership or to the exclusive licensing of results, up to 4 years after the end of the action.
For applicants and beneficiaries, little is expected to change, as in previous years this condition had been part of the General Annexes, having legal force across all parts of Horizon Europe (including the Health Cluster topics). In practise, the granting authority may invoke the “right to object” under specific conditions, which so far has happened in very rare occasions over the many years of Horizon Europe.
More details below from Annex 5 of the General Model Grant Agreement:
Where the call conditions in Horizon Europe actions provide for the right to object to transfers or licensing, the granting authority may — up to four years after the end of the action — object to a transfer of ownership or the exclusive licensing of results, if:
the beneficiaries which generated the results have received funding under the grant
it is to a legal entity established in a non-EU country not associated with Horizon Europe, and
the granting authority considers that the transfer or licence is not in line with EU interests.
Beneficiaries that intend to transfer ownership or grant an exclusive licence must formally notify the granting authority before the intended transfer or licensing takes place and:
identify the specific results concerned
describe in detail the new owner or licensee and the planned or potential exploitation of the results, and
include a reasoned assessment of the likely impact of the transfer or licence on EU interests, in particular regarding competitiveness as well as consistency with ethical principles and security considerations.
The granting authority may request additional information.
If the granting authority decides to object to a transfer or exclusive licence, it must formally notify the beneficiary concerned within 60 days of receiving notification (or any additional information it has requested).
No transfer or licensing may take place in the following cases:
pending the granting authority decision, within the period set out above
if the granting authority objects
until the conditions are complied with, if the granting authority objection comes with conditions.
A beneficiary may formally notify a request to waive the right to object regarding intended transfers or grants to a specifically identified third party, if measures safeguarding EU interests are in place. If the granting authority agrees, it will formally notify the beneficiary concerned within 60 days of receiving notification (or any additional information requested).
Read it on the EU portal ↗Answered 28 Jun 2026
Confirm the current call documents and submission conditions with the funding authority.
View on EU portal ↗Source: EU Funding & Tenders Portal · synced 2026-11-09
A free account keeps your shortlist and sends deadline reminders. The EUACC connector brings this call, its FAQs, past winners and similar calls into Claude or ChatGPT, so you can check fit and draft with sources.